Compare EEFT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEFT | HRMY |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 1996 | 2020 |
| Metric | EEFT | HRMY |
|---|---|---|
| Price | $71.07 | $32.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $73.00 | $48.08 |
| AVG Volume (30 Days) | 981.5K | ★ 1.1M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.05 | ★ 7.97 |
| EPS | ★ 5.05 | 2.63 |
| Revenue | ★ $4,244,200,000.00 | $868,453,000.00 |
| Revenue This Year | $3.12 | $18.17 |
| Revenue Next Year | $4.19 | $13.71 |
| P/E Ratio | $27.81 | ★ $18.70 |
| Revenue Growth | 6.38 | ★ 21.51 |
| 52 Week Low | $57.48 | $25.90 |
| 52 Week High | $83.97 | $43.49 |
| Indicator | EEFT | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 63.73 | 32.00 |
| Support Level | $67.71 | $33.49 |
| Resistance Level | $74.95 | $35.47 |
| Average True Range (ATR) | 2.47 | 1.77 |
| MACD | 0.70 | -0.13 |
| Stochastic Oscillator | 98.32 | 25.69 |
Euronet Worldwide Inc is a provider of electronic financial transaction solutions. It offers payment and transaction processing and distribution solutions to financial institutions, retailers, service providers, and individual consumers. The company's product offerings include comprehensive ATM, POS, card outsourcing, card issuing, and merchant acquiring services, software solutions, money transfer services, etc. Its reportable operating segments are EFT Processing, epay, and Money Transfer. Maximum revenue is derived from its Money Transfer segment, which provides money transfer services across the world under the brand names Ria, AFEX, IME, and xe. Geographically, the company generates maximum revenue from the United States, followed by Germany, India, France, Greece, and other regions.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.